• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coverage

Latest content

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecAiforia TechnologiesBiohitOrionModulight

Latest content

ShowingAll content types

Bioretec Q2'26: There is growth, but the trend is not yet clear

Research 14.08.2026, 10.03 by Antti Siltanen
Bioretec

Bioretec H1'26: Expansion of the product portfolio into spinal applications progresses

Video 13.08.2026, 13.16 by Antti Siltanen
Bioretec

Orion: Tilbageslag i fase 3-studie med levosimendan

Analyst Comment 11.08.2026, 07.12 by Antti Siltanen
Orion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate

Analyst Comment 11.08.2026, 08.25 by Antti Siltanen
Nexstim

Bioretec Q2'26 preview: Strong growth and improved earnings expected

Analyst Comment 10.08.2026, 08.25 by Antti Siltanen
Bioretec

Biohit H1'26: Strong earnings clouded by weak cash flow

Research 06.08.2026, 09.50 by Antti Siltanen
Biohit

Aiforia secured a 20 MEUR financing agreement with the EIB

Analyst Comment 03.08.2026, 08.19 by Antti Siltanen, Antti Luiro
Aiforia Technologies

Biohit H1'26 preview: Moderate growth against weak comparison period

Analyst Comment 31.07.2026, 07.23 by Antti Siltanen
Biohit

Faron reports first OS results from frontline MDS patients

Analyst Comment 28.07.2026, 08.33 by Antti Siltanen
Faron Pharmaceuticals

Aiforia: We diagnose a growth deficiency

Research 23.07.2026, 09.25 by Antti Siltanen
Aiforia Technologies